CA2414247C - Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside - Google Patents
Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside Download PDFInfo
- Publication number
- CA2414247C CA2414247C CA2414247A CA2414247A CA2414247C CA 2414247 C CA2414247 C CA 2414247C CA 2414247 A CA2414247 A CA 2414247A CA 2414247 A CA2414247 A CA 2414247A CA 2414247 C CA2414247 C CA 2414247C
- Authority
- CA
- Canada
- Prior art keywords
- skin
- phytoestrogen
- composition
- mmpi
- adverse effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- -1 triterpenoid glycoside Chemical class 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 18
- 229930182470 glycoside Natural products 0.000 title claims description 6
- 239000002537 cosmetic Substances 0.000 title abstract description 18
- 239000003075 phytoestrogen Substances 0.000 claims abstract description 33
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims abstract description 29
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims abstract description 29
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 230000002411 adverse Effects 0.000 claims abstract 13
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 claims description 17
- 229960003696 ilomastat Drugs 0.000 claims description 16
- 230000032683 aging Effects 0.000 claims description 13
- 206010051246 Photodermatosis Diseases 0.000 claims description 11
- 230000008845 photoaging Effects 0.000 claims description 11
- 241000906543 Actaea racemosa Species 0.000 claims description 8
- 235000005301 cimicifuga racemosa Nutrition 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 6
- 230000001603 reducing effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940061349 black cohosh extract Drugs 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 claims description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims description 2
- 229950001858 batimastat Drugs 0.000 claims description 2
- 229940100539 dibutyl adipate Drugs 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims description 2
- 229950008959 marimastat Drugs 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 abstract description 47
- 239000000262 estrogen Substances 0.000 abstract description 33
- 229940011871 estrogen Drugs 0.000 abstract description 33
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 8
- 229940124761 MMP inhibitor Drugs 0.000 abstract description 8
- 230000003467 diminishing effect Effects 0.000 abstract description 8
- 229960005309 estradiol Drugs 0.000 abstract description 5
- 230000001076 estrogenic effect Effects 0.000 abstract description 5
- 230000000391 smoking effect Effects 0.000 abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 3
- 235000019504 cigarettes Nutrition 0.000 abstract description 3
- 239000003687 estradiol congener Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 150000003431 steroids Chemical class 0.000 abstract description 3
- 229930182833 estradiol Natural products 0.000 abstract description 2
- 230000008832 photodamage Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- 230000037303 wrinkles Effects 0.000 description 23
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 10
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 238000009164 estrogen replacement therapy Methods 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108010030545 N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- KDHQQKMAQNCJPB-UHFFFAOYSA-N hydron;1-(2-methyl-3-nitrophenoxy)-3-(propan-2-ylamino)propan-2-ol;chloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=CC([N+]([O-])=O)=C1C KDHQQKMAQNCJPB-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21508700P | 2000-06-29 | 2000-06-29 | |
| US60/215,087 | 2000-06-29 | ||
| PCT/US2001/020945 WO2002019982A2 (en) | 2000-06-29 | 2001-06-29 | Cosmetic composition and method for reducing or preventing wrinkling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2414247A1 CA2414247A1 (en) | 2002-03-14 |
| CA2414247C true CA2414247C (en) | 2012-11-27 |
Family
ID=22801588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2414247A Expired - Fee Related CA2414247C (en) | 2000-06-29 | 2001-06-29 | Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6713074B2 (enExample) |
| EP (1) | EP1359897A2 (enExample) |
| JP (1) | JP5106739B2 (enExample) |
| AU (2) | AU7311501A (enExample) |
| CA (1) | CA2414247C (enExample) |
| WO (1) | WO2002019982A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083321A1 (en) * | 2001-09-25 | 2003-05-01 | Lerner David S. | Composition and method for minimizing or avoiding adverse effects of vesicants |
| US20080139512A1 (en) * | 2002-09-25 | 2008-06-12 | Quick-Med Technologies, Inc. | Method for minimizing or avoiding adverse effects of vesicants |
| US7060304B2 (en) * | 2003-04-16 | 2006-06-13 | Access Business Group International Llc | Skin whitening compositions containing black cohosh extract |
| US6994874B2 (en) * | 2003-04-16 | 2006-02-07 | Access Business Group International, Llc | Skin whitening compositions containing asparagus extract |
| CA2526222A1 (en) * | 2003-05-16 | 2004-12-02 | Arriva Pharmaceuticals, Inc. | Treatment of respiratory disease associated with matrix metalloprotease inhibitors |
| FR2859908A1 (fr) * | 2003-09-24 | 2005-03-25 | Oreal | Composition comprenant au moins un inhibiteur de metalloproteinase et au moins un agent myorelaxant ou relaxant |
| JP4803698B2 (ja) * | 2004-11-02 | 2011-10-26 | 丸善製薬株式会社 | 抗老化剤、エストロゲン様作用剤、抗男性ホルモン剤、育毛剤、テストステロン５α−レダクターゼ阻害剤、皮膚化粧料及び頭髪化粧料 |
| BRPI0615588A2 (pt) * | 2005-08-31 | 2011-05-24 | Serentis Ltd | uso de um inibidor de aureolisina para o tratamento de condições inflamatórias da pele caracterizadas por colonização com staphylococcus aureus |
| US20070142905A1 (en) * | 2005-12-16 | 2007-06-21 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
| JP5661994B2 (ja) * | 2008-01-04 | 2015-01-28 | クラシエ製薬株式会社 | 抗ストレス・疲労防止、肌のキメ改善又はシワ改善・防止効果を有する組成物又は内服剤 |
| US20090299466A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Matrix Metalloproteinase Inhibitors |
| US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
| GB201110777D0 (en) | 2011-06-24 | 2011-08-10 | Aqua Bio Technology Asa | Methods and uses |
| EP3973967A1 (en) | 2012-12-21 | 2022-03-30 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| TWI480057B (zh) * | 2013-07-08 | 2015-04-11 | Univ China Medical | 咖啡酸醯胺衍生物之應用 |
| US10166412B2 (en) | 2014-12-30 | 2019-01-01 | Conopco, Inc. | Skin lightening composition comprising 4-hexylresorcinol and ilomastat |
| CA2971907C (en) * | 2014-12-30 | 2023-08-15 | Unilever Plc | A skin lightening composition comprising niacinamide and ilomastat |
| KR102124065B1 (ko) * | 2018-08-17 | 2020-06-17 | 서울대학교산학협력단 | 식물 추출물을 함유하는 피부 주름 개선용 조성물 |
| CN114516917B (zh) * | 2020-11-20 | 2022-11-18 | 广东东阳光药业有限公司 | 人源化抗TrkA的抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5268384A (en) | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| FR2717389B1 (fr) * | 1994-03-18 | 1996-06-07 | Lvmh Rech | Utilisation du ginsénoside Ro ou d'un extrait végétal en contenant pour stimuler la synthèse du collagène. |
| US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
| US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
| US6338855B1 (en) * | 1996-10-25 | 2002-01-15 | The Procter & Gamble Company | Cleansing articles for skin and/or hair which also deposit skin care actives |
| TWI234467B (en) | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
| US5885596A (en) | 1997-07-23 | 1999-03-23 | Bristol-Myers Squibb Company | Methods and compositions for fine lines and/or wrinkles |
| US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
| US6030620A (en) * | 1997-07-25 | 2000-02-29 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing an organic extract of chick pea |
| DE19812204A1 (de) * | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
| FR2782919B1 (fr) * | 1998-09-04 | 2001-05-25 | Roc Sa | Composition contre le vieillissement et son utilisation |
| JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| US6139828A (en) | 1999-06-02 | 2000-10-31 | Hair Associates, Llc | Hair care formulations |
| US6358517B1 (en) * | 1999-10-22 | 2002-03-19 | Unilever Home & Personal Care Usa, Division Of Conopco | Cosmetic compositions containing resveratrol and retinoids |
| WO2001043711A1 (en) * | 1999-12-14 | 2001-06-21 | Unilever Plc | Cosmetic skin conditioning compositions containing red yeast rice extract |
| US20020010162A1 (en) * | 2000-03-02 | 2002-01-24 | Raul Fleischmajer | Treatment of psoriasis with matrix metalloproteinase inhibitors |
-
2001
- 2001-06-29 AU AU7311501A patent/AU7311501A/xx active Pending
- 2001-06-29 WO PCT/US2001/020945 patent/WO2002019982A2/en not_active Ceased
- 2001-06-29 EP EP01952355A patent/EP1359897A2/en not_active Withdrawn
- 2001-06-29 US US09/896,566 patent/US6713074B2/en not_active Expired - Lifetime
- 2001-06-29 CA CA2414247A patent/CA2414247C/en not_active Expired - Fee Related
- 2001-06-29 AU AU2001273115A patent/AU2001273115C1/en not_active Ceased
- 2001-06-29 JP JP2002524467A patent/JP5106739B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002019982A3 (en) | 2003-07-24 |
| JP5106739B2 (ja) | 2012-12-26 |
| AU2001273115C1 (en) | 2009-03-26 |
| US6713074B2 (en) | 2004-03-30 |
| CA2414247A1 (en) | 2002-03-14 |
| EP1359897A2 (en) | 2003-11-12 |
| JP2004508317A (ja) | 2004-03-18 |
| AU7311501A (en) | 2002-03-22 |
| AU2001273115B2 (en) | 2005-06-16 |
| WO2002019982A2 (en) | 2002-03-14 |
| US20020054922A1 (en) | 2002-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2414247C (en) | Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside | |
| AU2001273115A1 (en) | Cosmetic composition and method | |
| US6110966A (en) | Triple action complex | |
| US6060070A (en) | Isoflavonoids for treatment and prevention of aging skin and wrinkles | |
| US5574063A (en) | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage | |
| CA2678135C (en) | Method for increasing hair growth using a creatine compound | |
| US5629002A (en) | Cosmetic or pharmaceutic preparations for improving hair quaility and stimulating growth of the hair | |
| EP0822816B1 (en) | Dermatological preparation for treating actinic keratoses | |
| JP2000086489A (ja) | 老化に対する組成物およびその使用 | |
| TW200526263A (en) | Holistic composition and method for reducing skin pigmentation | |
| JP2004508317A5 (enExample) | ||
| US11110117B2 (en) | Skin preparation composition for external use containing complex hyaluronic acid | |
| KR20230074749A (ko) | 모발, 두피 및 피부 트리트먼트 조성물 | |
| US20020168325A1 (en) | NOS inhibitors for treatment of wrinkles | |
| US20040185127A1 (en) | Cosmetic composition and method | |
| WO1991001128A1 (en) | Skin composition to repair the efffects of photoaging | |
| CN113693966A (zh) | 一种创新型美白亮采祛斑霜及其制备方法 | |
| JP2001503447A (ja) | 老化皮膚の処置用組成物および方法 | |
| CN1081025C (zh) | 一种含氢醌单丙酸脂和α－羟基酸的祛斑增白化妆品 | |
| US20250295562A1 (en) | Formulation for treatment of melasma, hyperpigmentation, and dark spots | |
| JP2006248953A (ja) | シワ改善剤及び皮膚外用組成物 | |
| ES2645535T3 (es) | Composiciones tópicas para tratar trastornos, enfermedades y dolencias inflamatorios | |
| TW200526265A (en) | Wrinkle-diminishing agent | |
| JPH10273422A (ja) | 頭髪用化粧料 | |
| MXPA99008250A (en) | Composition against the ageing and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180629 |